PMaROD: Precision Medicine Approaches to Renal Osteodystrophy

Sponsor

Thomas Nickolas, MD MS (Other)

Overall Status

Recruiting

CT.gov ID

NCT05880914

Collaborator

Indiana University School of Medicine (Other)

Enrollment

Location

54.3

Anticipated Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease patients and parathyroid hormone and bone alkaline phosphatase have insufficient accuracy for turnover type to safely and confidently guide treatment of renal osteodystrophy. In the present investigation, the investigators will study a microRNA approach as a novel non-invasive biomarker of turnover for renal osteodystrophy.

Condition or Disease	Intervention/Treatment	Phase
Renal Osteodystrophy Chronic Kidney Diseases CKD-MBD Bone Turnover Rate Disorder Secondary Hyperparathyroidism

Detailed Description

Renal osteodystrophy (ROD) is a complex disorder of cortical bone quality and strength. Impaired cortical bone is due to the combined actions of elevated parathyroid hormone (PTH) levels and changes in bone hormones as a result of kidney failure. ROD affects nearly all patients with chronic kidney disease (CKD) and results in cortical bone loss, cortical-type fractures and cardiovascular events. The current goal of ROD treatment, to reduce high bone turnover due to renal hyperparathyroidism, is contraindicated in the presence of low turnover yet reliable ways to determine low turnover status are lacking. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend that treatment is guided by the biomarkers PTH and bone specific alkaline phosphatase (BSAP) and not to treat when turnover is low. However, despite these recommendations, cortical-type fracture incidence has doubled in dialysis patients over the past 25-years, a failure in fracture reduction due in part to PTH and BSAP being developed to identify turnover in trabecular rather than cortical bone. Furthermore, although KDIGO recommends tetracycline-labeled bone biopsy to define turnover and guide treatment, the histomorphometry is also based on analysis of trabecular and not cortical bone, the latter being the primary site of PTH action. Published preliminary data for this proposal suggest that trabecular turnover is a poor surrogate for cortical turnover, with only moderate correlations between bone compartments (R2 59%). Thus, there is an unmet need to identify biomarkers with high diagnostic accuracy and clinical utility for the identification of low cortical turnover, used without or without trabecular turnover, to guide treatment decisions and for use in clinical trials. In published data, the investigators hypothesized that an a priori defined subset of microRNAs (miRNA) that regulate osteoblast (miRNA-30c, 30b, 125b) and osteoclast (miRNA-155) development would be accurate biomarkers of low cortical turnover. In 23 CKD patients with bone biopsies, the areas under the curve for discrimination of low from non- low turnover were 0.866, 0.813, 0.813, and 0.723 for miRNAs-30b, 30c, 125b and 155 respectively, 0.925 for a panel of the 4 four miRNAs combined, while PTH and BSAP, individually and together, did not discriminate in this population. Based on these findings, the central hypothesis is that circulating miRNAs discriminate ROD cortical bone subtype. In a cohort of 90 CKD patients with low, normal, and high turnover (30/group; Aim 1) we will use miRNAseq to identify novel miRNAs that correlate with ROD type and determine if their combination with the preliminary panel enhances discrimination. In 40 ROD patients managed with strategies that change turnover from high to low or low to high (n=20/group; Aim 2), the investigators will determine if changes in histology-based turnover are reflected by changes in the optimized panel and if the circulating miRNA panel mirrors bone-tissue miRNA expression. Then, the investigators will determine if the panel is related to bone quality and strength (Aim 3). The studu's results will determine if the circulating panel can serve as a biomarker for guiding ROD management. This high impact proposal has the potential to result in a paradigm shift in the non-invasive diagnosis and management of ROD.

Study Design

Study Type:

Observational

Anticipated Enrollment :

40 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

Precision Medicine Approaches to Renal Osteodystrophy

Actual Study Start Date :

Dec 21, 2022

Anticipated Primary Completion Date :

Aug 17, 2026

Anticipated Study Completion Date :

Jun 30, 2027

Outcome Measures

Primary Outcome Measures

To determine the utility of a miRNA panel to discriminate changes in bone turnover [Five years]
This study will determine whether a panel of miRNAs in blood can be used to determine changes in bone turnover and be used in future studies to guide the starting and stopping of treatment for bone disease in patients with kidney failure
To determine whether of a miRNA panel that identifies bone turnover type is able to also identify with bone quality [Five Years]
Bone turnover directly affects bone strength through alterations in bone quality. Our goal is to utilize the circulating miRNA panel to fully assess bone quality in patients with renal osteodystrophy

Secondary Outcome Measures

To confirm that miRNAs in circulation reflect miRNAs in bone-tissue [Five Years]
The miRNA panel that identifies turnover type in blood will be compared to the miRNAs that are expressed in bone tissue derived from iliac crest bone biopsy
To confirm that miRNAs in circulation reflect changes in bone based on bone imaging [Five Years]
Pre- and post-treatment changes in the circulating miRNA profile will be compared to changes in bone imaging by HR-pQCT

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Study participant has provided informed consent
Age ≥ 18 years
CKD Stages 3-5D regardless of kidney transplantation status
CKD5D patients receiving maintenance hemodialysis for at least 3 months
Clinically indicated treatment for renal hyperparathyroidism, renal osteodystrophy and/or Osteoporosis
PTH, BSAP and CTX meets defined thresholds for low or high turnover ROD type or a Bone biopsy evidence of low or high turnover based

Exclusion Criteria:

Currently receiving treatment in an investigational device or drug study, or less than 30 days since ending treatment on an investigational device or drug study(s)
Currently receiving investigational procedures/drugs from another study while participating in this study
Use of etelcalcetide, bisphosphonate, denosumab, teriparatide, abaloparatide or romosozumab during the 6 months prior to study enrollment; however, participant can be included if being treated with bone active agent but will have class change to an agent that will result in a change in bone turnover from low to high or high to low
New use of cinacalcet over the prior 6 months
Use of Zoledronic Acid (Reclast) less than 24 months from study enrollment for patients with eGFR <30mL/minute
Anticipated or scheduled kidney transplant during the study period or less than 1 year from receiving a kidney transplant
For patients with a solid organ transplant, less than 1 year from receiving the transplant
Patient has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator
Metabolic bone diseases not related to the kidney (e.g., Paget's, Osteogenesis Imperfecta)
Endocrinopathy (e.g., untreated hyperthyroidism)
Malignancy within the last 5 years (except non-melanoma skin cancers or cervical carcinoma in situ)
Patient is pregnant or nursing
Weight >300 pounds (scanner limitation)
Allergy to tetracycline or demeclocycline
Patients on non-aspirin anticoagulants that cannot be reasonably held for biopsy
Patient unable to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the patient and Investigator's knowledge